Scholar Rock's Apitegromab Gains FDA Fast Track for FSHD as Phase 2 Trial Begins
Event summary
- Scholar Rock's apitegromab receives FDA Fast Track and Orphan Drug designations for FSHD treatment.
- Phase 2 FORGE trial for apitegromab in FSHD patients has begun dosing.
- FORGE trial will enroll ~60 participants, with primary endpoint measuring lean muscle volume change via MRI.
- Apitegromab is designed to inhibit myostatin activation, aiming to increase muscle mass and strength.
The big picture
Scholar Rock's progress with apitegromab underscores the growing focus on targeted therapies for rare neuromuscular diseases. The FDA's Fast Track designation highlights the unmet medical need in FSHD, a condition with no approved treatments. The Phase 2 FORGE trial could validate Scholar Rock's myostatin inhibition approach, potentially positioning apitegromab as a first-in-class therapy.
What we're watching
- Clinical Efficacy
- Whether apitegromab can demonstrate meaningful improvements in muscle volume and function in FSHD patients.
- Regulatory Momentum
- The pace at which FDA Fast Track designation accelerates apitegromab's development and review process.
- Market Expansion
- How Scholar Rock leverages its myostatin platform to expand into additional rare neuromuscular diseases.